Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

1.6K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.6K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

7.5K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.5K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

8.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Antigen-scaffolds loaded with hyper-stable neoleukin-2/15 expand antigen-specific T cells with a favorable phenotype for adoptive cell therapy.

Frontiers in immunology·2026
Same author

Stable global repertoire architecture masks short-term clonal remodeling in intratumoral TCR repertoires.

Frontiers in immunology·2026
Same author

Driving CAR therapies beyond T cells.

Trends in cancer·2026
Same author

Dextran-based T-cell expansion nanoparticles for manufacturing CAR T cells with augmented efficacy.

Nature communications·2026
Same author

A yeast surface display platform for characterizing CAR T cell responses to cancer antigens.

Nature communications·2025
Same author

Mapping real-time metabolic kinetics of expanded CAR T cells using hyperpolarized <sup>13</sup>C-glucose and metabolomics.

Scientific reports·2025

Related Experiment Video

Updated: Dec 15, 2025

Non-Viral Engineering of Primary Human T Cells via Homology-Mediated End-Joining Targeted Integration of Large DNA Templates
06:10

Non-Viral Engineering of Primary Human T Cells via Homology-Mediated End-Joining Targeted Integration of Large DNA Templates

Published on: May 9, 2025

781

Augmenting engineered T-cell strategies in solid cancers through epigenetic priming.

Aaraby Y Nielsen1, Maria Ormhøj2, Sofie Traynor1

  • 1Department of Cancer and Inflammation Research, Institute of Molecular Medicine, University of Southern Denmark, Odense, Denmark.

Cancer Immunology, Immunotherapy : CII
|July 11, 2020
PubMed
Summary

Adoptive cell transfer (ACT) shows promise in blood cancers but struggles with solid tumors due to challenges like tumor microenvironments. Combining epigenetic modulators with ACT may enhance T-cell therapies for solid cancers.

Keywords:
Cancer immunotherapyCancer/testis antigensCombination therapyEpigenetic drugsGenetically modified T cellsSolid tumors

More Related Videos

Enrich and Expand Rare Antigen-specific T Cells with Magnetic Nanoparticles
09:28

Enrich and Expand Rare Antigen-specific T Cells with Magnetic Nanoparticles

Published on: November 17, 2018

11.9K
Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells
09:04

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

1.2K

Related Experiment Videos

Last Updated: Dec 15, 2025

Non-Viral Engineering of Primary Human T Cells via Homology-Mediated End-Joining Targeted Integration of Large DNA Templates
06:10

Non-Viral Engineering of Primary Human T Cells via Homology-Mediated End-Joining Targeted Integration of Large DNA Templates

Published on: May 9, 2025

781
Enrich and Expand Rare Antigen-specific T Cells with Magnetic Nanoparticles
09:28

Enrich and Expand Rare Antigen-specific T Cells with Magnetic Nanoparticles

Published on: November 17, 2018

11.9K
Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells
09:04

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

1.2K

Area of Science:

  • Immunotherapy
  • Cancer Biology
  • Epigenetics

Background:

  • T-cell receptor (TCR) and chimeric antigen receptor (CAR)-based adoptive cell transfer (ACT) therapies have shown success in hematological malignancies.
  • However, ACT efficacy in solid tumors is limited by challenges including target identification, antigen heterogeneity, T-cell trafficking, and the tumor microenvironment (TME).

Purpose of the Study:

  • To review the current literature on ACT for solid tumors.
  • To explore the potential of combining epigenetic modulators with ACT strategies to overcome current limitations.

Main Methods:

  • Literature review of existing studies on ACT in solid tumors.
  • Analysis of challenges hindering ACT efficacy in solid tumors.
  • Exploration of epigenetic priming as a strategy to enhance T-cell function.

Main Results:

  • Solid tumors present unique hurdles for ACT compared to hematological cancers.
  • Epigenetic modifications of tumor cells and the TME are potential strategies to improve ACT outcomes.
  • Combining epigenetic modulators with ACT may augment the efficacy of TCR- and CAR-engineered T cells.

Conclusions:

  • ACT for solid tumors requires innovative approaches to overcome inherent biological barriers.
  • Epigenetic modulation presents a promising avenue for enhancing the effectiveness of engineered T-cell therapies.
  • Future research should focus on integrating epigenetic therapies with ACT to improve clinical outcomes in solid cancer treatment.